In order to fully execute on the advantages of Hera’s SRG OncoRat, in vivo xenografts must be accompanied with optimized cell culture techniques. Hera has developed a process specifically designed to improve cell culture for in vitro and in vivo oncology studies. One key component is the upfront optimization of cell protocols. Hera has the expertise to adopt or modify existing cell culture methods for any cell line. Click here to see a list of 75+ different cells we have worked with either in a cell culture scope or in vivo xenograft studies.
Request A Proposal
Download Publications
In vitro VCaP cell assay results

VCaP cells were plated onto 96-well plates and allowed 72hours for adhering to plate. Cells were then adjusted to phenol-red-free RPMI 1640 with 5% CSS for another 48 hours. After 7days of incubation with Enz or Bic in agonist or antagonist mode (using synthetic androgen R1881), CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed using Cytation 3 Cell Imaging Multi-Mode reader (BioTek). Dose-response curves and percent viability of the samples in agonist and antagonist mode were calculated.
Results:
Bic effectively induced proliferation of VCaP cells in dose-dependent manner, where as Enz decrease cell viability at higher doses. Both Bic and Enz antagonized the proliferative effect of synthetic androgen R1881.